Press release
Alzheimer's Disease Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Alzheimer's Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Alzheimer's Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Alzheimer's Disease Pipeline Report
* On 29 August 2025, UCB Biopharma SRL announced a study to investigate the effect of bepranemab versus placebo on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) through Week 80 in participants with prodromal or mild Alzheimer's Disease (AD).
* On 27 August 2025, Bristol-Myers Squibb initiated a Phase 3 study to evaluate the efficacy and safety of KarXT + KarX-EC for the treatment of cognitive impairment associated with mild to moderate Alzheimer's Disease.
* On 27 August 2025, Eli Lilly and Company announced a study designed to assess the difference in the time to developing or worsening memory, thinking, or functional problems due to Alzheimer's Disease, comparing participants receiving the investigational drug to those receiving placebo.
* On 24 August 2025, Beijing Joekai Biotechnology LLC initiated a study aimed at evaluating the efficacy and safety of two doses of 50561 compared with placebo in participants diagnosed with mild to moderate Alzheimer's Disease.
* DelveInsight's Alzheimer's Disease Pipeline report depicts a robust space with 200+ active players working to develop 220+ pipeline therapies for Alzheimer's Disease treatment.
* The leading Alzheimer's Disease Companies such as Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuticals, Eisai Inc., T3D Therapeutics, Merck Sharp & Dohme, Shanghai Hengrui Pharmaceutical, NeuroSense Therapeutics, Pharmazz, Johnson & Johnson Innovative Medicine, NKGen Biotech, LEXEO Therapeutics, Inventage Lab, Neumora Therapeutics, Takeda, Perha Pharmaceuticals, Luye Pharma Group Ltd., Eli Lilly and Company, Prothena, Therabest Korea, Neurotez, TRIMTECH Therapeutics, Lexeo Therapeutics and others.
* /Promising Alzheimer's Disease Pipeline Therapies such as SAR110894, Donepezil, Aricept, INM-176, Wujia Yizhi granules, CPC-201, ENA713, memantine ER, Gantenerumab, Solanezumab, Florbetapir F18, ITI-1284 and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Alzheimer's Disease Drug Development Pipeline 2025 [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Alzheimer's Disease Emerging Drugs Profile
* AR1001: AriBio Co., Ltd.
AR1001 is a PDE5 inhibitor being developed as an investigational oral agent for the treatment of Alzheimer's disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity, demonstrating multiple mechanisms of action for disease modifying effects that may ameliorate the course of AD. AR1001 has also demonstrated robust reduction of Hyperphosphorylated Tau proteins in pre-clinical models as well as in a Phase II trial. It is being developed by the South Korean biopharmaceutical company, Aribio Co. AR1001 is 10-fold more potent at inhibiting PDE5 relative to sildenafil, and has superior BBB penetrance. Currently, the drug is in the Phase III stage of its development for the treatment of Alzheimer's disease.
* AGB101: AgeneBio
AGB101 is a proprietary extended-release formulation of Levetiracetam, an FDA-approved anti-epileptic. AGB101 is being evaluated for Mild Cognitive Impairment (MCI) due to Alzheimer's Disease (AD) as a once-daily dose that is given to patients at approximately one-twelfth of the dose most commonly prescribed for epilepsy. AGB101 is being investigated for the treatment of hippocampal overactivity and to assess its ability to control progression to Alzheimer's dementia. AGB101's mechanism of action is inhibition of the synaptic protein SV2A. The rationale for AGB101's use in MCI stems from suggestions that tamping down hippocampal neuron hyperactivity in people in the early stages of AD dementia may prevent the spread of tau pathology and disease progression. Currently, the drug is in the Phase II/III stage of its development for the treatment of Alzheimer's Disease.
* AMX0035: Amylyx Pharmaceuticals Inc
AMX0035 is an investigational, oral, fixed-dose combination of sodium Phenylbutyrate (PB) and Taurursodiol (TURSO). This combination therapy is designed to reduce neuronal death through two mechanisms: sodium phenylbutyrate decreases Endoplasmic Reticulum (ER) stress (by upregulating the master chaperone regulator DJ-1) and TUDCA mitigates mitochondrial dysfunction (by incorporating into the mitochondrial membrane and increasing apoptotic threshold). AMX0035 is designed to slow or mitigate neurodegeneration by targeting endoplasmic reticulum (ER) stress and mitochondrial dysfunction, two connected central pathways that lead to cell death and neurodegeneration. Preclinical studies have provided evidence that AMX0035 may reduce cell death and improve cellular function, also supporting the synergistic effect of AMX0035 compared to individual compounds. . Currently, the drug is in the Phase II stage of its development for the treatment of Alzheimer's disease.
* IVL3003: Inventage Lab., Inc.
IVL3003 is an investigational therapeutic candidate being developed for the treatment of Alzheimer's disease (AD). It is designed to target key pathological processes associated with AD, potentially offering neuroprotective and disease-modifying effects. While the exact mechanism of action (MoA) has not been publicly disclosed, IVL3003 is part of a new wave of innovative approaches aiming to address unmet needs in neurodegenerative disorders. The compound is currently in early-stage clinical development. Its progression highlights continued efforts to develop effective therapies for cognitive decline and neurodegeneration in AD. Currently, the drug is in the Phase I/II stage of its development for the treatment of Alzheimer's disease (AD).
* BHV-8000: Biohaven Pharmaceuticals
BHV-8000 is a first-in-class, oral, brain-penetrant, dual TYK2/JAK1 selective inhibitor. The TYK2 and JAK1 signal transduction pathways mediate highly complementary immune and inflammatory signalling events. Dual inhibition of TYK2 and JAK1 can effectively block Th17 cell generation, Type I IFN signaling, and inflammation. By reducing the inflammatory impacts of microglia, astrocytes, and infiltrating T-lymphocytes, BHV-8000 breaks the cycle of neuroinflammation. The drug is currently in Phase I stage of clinical trial evaluation for the treatment of Alzheimer's disease.
The Alzheimer's Disease Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Alzheimer's Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer's Disease Treatment.
* Alzheimer's Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Alzheimer's Disease Drugs development pipeline based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alzheimer's Disease market
Explore groundbreaking therapies and clinical trials in the Alzheimer's Disease Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Alzheimer's Disease Drugs [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Alzheimer's Disease Companies
Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuticals, Eisai Inc., T3D Therapeutics, Merck Sharp & Dohme, Shanghai Hengrui Pharmaceutical, NeuroSense Therapeutics, Pharmazz, Johnson & Johnson Innovative Medicine, NKGen Biotech, LEXEO Therapeutics, Inventage Lab, Neumora Therapeutics, Takeda, Perha Pharmaceuticals, Luye Pharma Group Ltd., Eli Lilly and Company, Prothena, Therabest Korea, Neurotez, TRIMTECH Therapeutics, Lexeo Therapeutics and others
Alzheimer's disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Alzheimer's Disease Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Alzheimer's Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Alzheimer's Disease Pipeline Report
* Coverage- Global
* Alzheimer's Disease Companies- Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuticals, Eisai Inc., T3D Therapeutics, Merck Sharp & Dohme, Shanghai Hengrui Pharmaceutical, NeuroSense Therapeutics, Pharmazz, Johnson & Johnson Innovative Medicine, NKGen Biotech, LEXEO Therapeutics, Inventage Lab, Neumora Therapeutics, Takeda, Perha Pharmaceuticals, Luye Pharma Group Ltd., Eli Lilly and Company, Prothena, Therabest Korea, Neurotez, TRIMTECH Therapeutics, Lexeo Therapeutics and others.
* Alzheimer's Disease Pipeline Therapies- SAR110894, Donepezil, Aricept, INM-176, Wujia Yizhi granules, CPC-201, ENA713, memantine ER, Gantenerumab, Solanezumab, Florbetapir F18, ITI-1284 and others.
* Alzheimer's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Alzheimer's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight's in-depth pipeline report today! @ Alzheimer's Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Alzheimer's disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Alzheimer's disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* AR1001: AriBio Co., Ltd.
* Mid Stage Products (Phase II/III)
* AGB101: AgeneBio
* Early Stage Products (Phase I/II)
* IVL3003: Inventage Lab., Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Alzheimer's disease Key Companies
* Alzheimer's disease Key Products
* Alzheimer's disease- Unmet Needs
* Alzheimer's disease- Market Drivers and Barriers
* Alzheimer's disease- Future Perspectives and Conclusion
* Alzheimer's disease Analyst Views
* Alzheimer's disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alzheimers-disease-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4167125 • Views: …
More Releases from ABNewswire
CloudMile Named Strategic Partner to Drive Enterprise AI Adoption Under Singapor …
Image: https://www.abnewswire.com/upload/2025/11/e9a6696a63928d207152b4c13b42d7d5.jpg
SINGAPORE - November 18th, 2025 - CloudMile, a leading AI company in Asia, has been appointed by Digital Industry Singapore (DISG) as one of the technology partners under the Enterprise Compute Initiative (ECI). This partnership marks a significant step in Singapore's national push to strengthen AI adoption and innovation across its enterprise landscape, as outlined in Budget 2025.
CloudMile Named Key Partner in Singapore's National AI Push Under Budget 2025
Launched…
Red Oak Hospice Brings Compassionate Care to Bridgeton: Tailored Palliative and …
Red Oak Hospice brings tailored palliative and hospice care to Bridgeton, ensuring local families receive compassionate support when they need it most.
Bridgeton, NJ - Red Oak Hospice, a trusted provider of compassionate end-of-life care, is proud to offer its expert hospice care services to families in the Bridgeton, NJ area. With a focus on personalized care, Red Oak Hospice ensures that individuals facing life-limiting illnesses and their families receive the…
MyIPNow Launches as a Next-Generation Suite of Free IP & Networking Tools for Gl …
So, there's this new thing called MyIPNow that just launched. It's basically a bunch of free tools for checking your IP address and other network stuff. It seems like they're trying to make it easier for everyone, no matter where they are, to get a handle on their internet connection and security. I've been hearing a bit about it, and it sounds like it could be pretty handy.
Key Takeaways
* MyIPNow…
Pixazo Launches Unified Visual AI API to Power the Next Generation of Multimodal …
Pixazo launches a Unified Visual AI API offering one-key access to 600+ models for image, video, audio, avatar, lip sync, and virtual try-on generation.
New Delhi, India - November 18, 2025 - Pixazo [https://www.pixazo.ai/] today announced the launch of its Unified Visual AI API, a single-key platform engineered to power the next great leap in digital creativity. As the world moves beyond text-based intelligence and into a multimodal era, Pixazo aims…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
